X

Trial Profile

A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berdazimer sodium (Primary)
Indications Molluscum contagiosum
Focus Therapeutic Use
Sponsors Novan Inc

Most Recent Events

03 Oct 2019 Results assessing safety and tolerability of berdazimer sodium gel coadministered with hydrogel were published in the Journal of the American Academy of Dermatology
10 Dec 2018 Primary endpoint (Proportion of Subjects Achieving Complete Clearance at Week 12) has been met, according to a Novan Inc media release.
10 Dec 2018 Results presented in the Novan Inc media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com